NASDAQ:CPRX - Catalyst Pharmaceuticals Stock Price, Price Target & More

$2.58 0.00 (0.00 %)
(As of 04/25/2018 08:54 AM ET)
Previous Close$2.58
Today's Range$2.58 - $2.58
52-Week Range$1.64 - $4.51
Volume1,344 shs
Average Volume641,351 shs
Market Capitalization$262.54 million
P/E Ratio-12.29
Dividend YieldN/A
Beta1.62

About Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals logoCatalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3. The company is also developing CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor for the treatment of refractory infantile spasms; and CPP-109, a vigabatrin tablet. It has license agreements with Northwestern University, New York University and the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Receive CPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CPRX
CUSIPN/A
Phone305-420-3200

Debt

Debt-to-Equity RatioN/A
Current Ratio20.00%
Quick Ratio20.00%

Price-To-Earnings

Trailing P/E Ratio-12.29
Forward P/E Ratio-7.17
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.79 per share
Price / Book3.27

Profitability

EPS (Most Recent Fiscal Year)($0.21)
Net Income$-18,410,000.00
Net MarginsN/A
Return on Equity-40.12%
Return on Assets-37.64%

Miscellaneous

Employees21
Outstanding Shares102,560,000

How to Become a New Pot Stock Millionaire

Catalyst Pharmaceuticals (NASDAQ:CPRX) Frequently Asked Questions

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals (NASDAQ:CPRX) posted its quarterly earnings data on Wednesday, March, 14th. The biopharmaceutical company reported ($0.06) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.06). View Catalyst Pharmaceuticals' Earnings History.

When is Catalyst Pharmaceuticals' next earnings date?

Catalyst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Catalyst Pharmaceuticals.

What price target have analysts set for CPRX?

4 brokers have issued 1-year target prices for Catalyst Pharmaceuticals' shares. Their predictions range from $5.00 to $8.00. On average, they expect Catalyst Pharmaceuticals' share price to reach $6.25 in the next twelve months. View Analyst Ratings for Catalyst Pharmaceuticals.

What are Wall Street analysts saying about Catalyst Pharmaceuticals stock?

Here are some recent quotes from research analysts about Catalyst Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "AT-014 Conditional Approval: Further Attestation to Strategy AT-014 receives a conditional licensure from the USDA. On December 20, Aratana announced that the USDA Center for Veterinary Biologics has granted AT-014 conditional marketing approval for the treatment of canine osteosarcoma. AT-014 is a canine cancer vaccine derived from listeria that targets HER2/neu, a causative mutation of canine osteosarcoma. In pilot studies, AT-014 treatment of dogs with osteosarcoma (n=18) increased their median overall survival (mOS) to 956 days compared to 423 days for historical controls (p<0.05). Therefore, following the USDA approval we believe that AT-014 can quickly become a preferred therapeutic option for this difficult-to-treat indication. With four product approvals in two years, we believe the success of AT-014 is a further attestation of management's strategy of bringing advanced human therapies to the veterinarian market."" (12/21/2017)
  • 2. According to Zacks Investment Research, "Catalyst Pharma posted narrower than expected loss in the third quarter of 2017. Earlier in 2016, the company received a refusal to file letter from the FDA in connection with the NDA for Firdapse. The company suffered a setback when it received a refusal to file letter for Firdapse from the FDA.  Nevertheless, the company expects to report top-line results from its second phase III study of Firdapse for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in early December 2017 and resubmit a new drug application (NDA) before the end of 2017. Catalyst has a limited number of candidates in its pipeline and is highly dependent on Firdapse’s approval for growth.  Meanwhile, the company is also developing Firdapse for additional indications. The company’s share price movement shows that the stock has outperformed the industry year to date. " (11/14/2017)

Who are some of Catalyst Pharmaceuticals' key competitors?

Who are Catalyst Pharmaceuticals' key executives?

Catalyst Pharmaceuticals' management team includes the folowing people:
  • Mr. Patrick J. McEnany, Co-Founder, Chairman, Chief Exec. Officer and Pres (Age 71)
  • Ms. Alicia Grande CPA, CMA, Chief Financial Officer, Chief Accounting Officer, VP and Treasurer (Age 47)
  • Dr. Steven R. Miller Ph.D., Chief Operating Officer and Chief Scientific Officer (Age 56)
  • Dr. Gary Ingenito M.D., Ph.D., Chief Medical Officer and Head of Regulatory Affairs (Age 62)
  • Mr. Brian Elsbernd, Sr. VP of Legal and Compliance (Age 54)

Has Catalyst Pharmaceuticals been receiving favorable news coverage?

Media stories about CPRX stock have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Catalyst Pharmaceuticals earned a media sentiment score of 0.12 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 46.68 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catalyst Pharmaceuticals' stock price today?

One share of CPRX stock can currently be purchased for approximately $2.58.

How big of a company is Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals has a market capitalization of $262.54 million. The biopharmaceutical company earns $-18,410,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Catalyst Pharmaceuticals employs 21 workers across the globe.

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]


MarketBeat Community Rating for Catalyst Pharmaceuticals (CPRX)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  251 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  363
MarketBeat's community ratings are surveys of what our community members think about Catalyst Pharmaceuticals and other stocks. Vote "Outperform" if you believe CPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Catalyst Pharmaceuticals in the last 12 months. Their average twelve-month price target is $6.25, suggesting that the stock has a possible upside of 142.25%. The high price target for CPRX is $8.00 and the low price target for CPRX is $5.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.25$6.25$6.25$5.50
Price Target Upside: 142.25% upside109.73% upside60.67% upside109.92% upside

Catalyst Pharmaceuticals (NASDAQ:CPRX) Consensus Price Target History

Price Target History for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals (NASDAQ:CPRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/15/2018HC WainwrightReiterated RatingBuy$6.00HighView Rating Details
12/1/2017Piper JaffraySet Price TargetPositive -> Buy$8.00LowView Rating Details
11/29/2017SunTrust BanksReiterated RatingBuy$6.00HighView Rating Details
11/1/2017Roth CapitalSet Price TargetBuy$5.00N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Catalyst Pharmaceuticals (NASDAQ:CPRX) Earnings History and Estimates Chart

Earnings by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals (NASDAQ:CPRX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.57)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.07)($0.07)($0.07)
Q2 20181($0.11)($0.11)($0.11)
Q3 20181($0.16)($0.16)($0.16)
Q4 20181($0.23)($0.23)($0.23)

Catalyst Pharmaceuticals (NASDAQ CPRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018($0.07)N/AView Earnings Details
3/14/2018Q4 2017($0.06)($0.06)ViewListenView Earnings Details
11/8/2017Q3 2017($0.06)($0.05)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.06)($0.0460)ViewListenView Earnings Details
5/10/2017Q1 2017($0.06)($0.06)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.07)($0.05)ViewN/AView Earnings Details
11/9/2016Q316($0.06)($0.05)ViewListenView Earnings Details
8/9/2016Q216($0.08)($0.06)ViewN/AView Earnings Details
5/10/2016Q116($0.07)($0.07)ViewN/AView Earnings Details
3/15/2016Q415($0.07)($0.07)ViewN/AView Earnings Details
11/9/2015Q3 2015($0.07)($0.06)ViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.06)ViewListenView Earnings Details
5/11/2015Q115($0.08)($0.06)ViewN/AView Earnings Details
3/16/2015Q414($0.07)($0.06)ViewN/AView Earnings Details
11/14/2014Q314($0.06)($0.06)ViewN/AView Earnings Details
8/14/2014Q214($0.08)($0.05)ViewN/AView Earnings Details
5/16/2014Q1 2014($0.08)($0.06)ViewN/AView Earnings Details
3/19/2014Q413($0.07)($0.02)ViewN/AView Earnings Details
11/14/2013Q3($0.07)($0.07)ViewN/AView Earnings Details
8/15/2013Q213($0.07)($0.06)ViewN/AView Earnings Details
5/16/2013Q1 2013($0.07)($0.04)ViewN/AView Earnings Details
4/2/2013Q4 2012($0.05)ViewN/AView Earnings Details
11/15/2012Q312($0.08)ViewN/AView Earnings Details
8/15/2012Q2 2012($0.04)($0.01)ViewN/AView Earnings Details
5/16/2012Q1 2012($0.08)($0.04)ViewN/AView Earnings Details
4/2/2012Q4 2011($0.06)($0.09)ViewN/AView Earnings Details
11/15/2011Q3 2011($0.07)($0.05)ViewN/AView Earnings Details
8/16/2011Q2 2011($0.08)($0.06)ViewN/AView Earnings Details
5/16/2011Q1 2011($0.08)ViewN/AView Earnings Details
4/1/2011Q4 2010($0.07)($0.04)ViewN/AView Earnings Details
11/16/2010Q3 2010($0.09)($0.05)ViewN/AView Earnings Details
8/13/2010Q2 2010($0.07)($0.07)ViewN/AView Earnings Details
5/18/2010Q1 2010($0.06)ViewN/AView Earnings Details
4/1/2010Q4 2009($0.06)ViewN/AView Earnings Details
11/12/2009Q3 2009($0.11)($0.09)ViewN/AView Earnings Details
8/7/2009Q2 2009($0.20)($0.13)ViewN/AView Earnings Details
5/14/2009Q1 2009($0.29)($0.22)ViewN/AView Earnings Details
3/27/2009Q4 2008($0.27)($0.27)ViewN/AView Earnings Details
11/14/2008Q3 2008($0.22)ViewN/AView Earnings Details
8/15/2008Q2 2008($0.14)($0.19)ViewN/AView Earnings Details
5/16/2008Q1 2008($0.12)($0.13)ViewN/AView Earnings Details
3/26/2008Q4 2007($0.07)($0.07)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Catalyst Pharmaceuticals (NASDAQ:CPRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Catalyst Pharmaceuticals (NASDAQ CPRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.30%
Institutional Ownership Percentage: 54.89%
Insider Trading History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals (NASDAQ CPRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/3/2018Patrick J McenanyInsiderBuy20,000$2.29$45,800.00View SEC Filing  
9/5/2017Patrick J McenanyInsiderBuy20,000$2.58$51,600.004,471,026View SEC Filing  
7/12/2016Charles B O'keeffeDirectorBuy20,000$0.81$16,200.00432,126View SEC Filing  
6/17/2016Philip H CoelhoDirectorBuy15,000$0.76$11,400.00159,987View SEC Filing  
6/14/2016Donald A DenkhausDirectorBuy50,000$0.65$32,500.00100,000View SEC Filing  
6/14/2016Patrick J McenanyCEOBuy105,300$0.65$68,445.004,393,109View SEC Filing  
4/26/2016Charles B O'keeffeDirectorBuy20,000$0.60$12,000.00412,126View SEC Filing  
4/26/2016Patrick J McenanyCEOBuy50,000$0.65$32,500.004,287,809View SEC Filing  
3/17/2016Philip H CoelhoDirectorBuy10,000$1.06$10,600.00158,287View SEC Filing  
3/16/2016Charles B O'keeffeDirectorBuy10,000$1.11$11,100.00392,126View SEC Filing  
1/11/2016Steve MillerCOOBuy7,933$1.80$14,279.40457,687View SEC Filing  
1/8/2016Charles B O'keeffeDirectorBuy5,000$1.94$9,700.00377,126View SEC Filing  
1/7/2016Donald A DenkhausDirectorBuy25,000$2.03$50,750.0050,000View SEC Filing  
12/28/2015Patrick J McenanyCEOBuy25,000$2.39$59,750.004,237,809View SEC Filing  
12/23/2015Charles B O'keeffeDirectorBuy5,000$2.41$12,050.00372,126View SEC Filing  
11/19/2015Charles B O'keeffeDirectorBuy5,000$2.30$11,500.00367,126View SEC Filing  
10/23/2015M Douglas WinshipVPSell22,800$3.34$76,152.0074,131View SEC Filing  
10/1/2015Patrick J McenanyCEOBuy10,000$2.81$28,100.004,137,262View SEC Filing  
5/1/2015David D MuthEVPBuy1,700$3.20$5,440.00View SEC Filing  
4/30/2015Charles B O'keeffeDirectorBuy10,000$3.29$32,900.00View SEC Filing  
4/28/2015David D MuthEVPBuy2,000$3.55$7,100.00View SEC Filing  
4/27/2015Donald A DenkhausDirectorBuy15,000$3.71$55,650.00View SEC Filing  
4/27/2015Patrick J McenanyCEOBuy5,000$3.79$18,950.00View SEC Filing  
4/24/2015Charles B O'keeffeDirectorBuy5,000$3.80$19,000.00View SEC Filing  
3/27/2015Donald A DenkhausDirectorBuy5,000$4.17$20,850.00View SEC Filing  
1/20/2015David D MuthEVPBuy21,000$2.96$62,160.00View SEC Filing  
1/13/2015Charles B O'keeffeDirectorBuy10,000$3.00$30,000.00View SEC Filing  
1/8/2015Patrick J McenanyCEOBuy50,000$2.80$140,000.00View SEC Filing  
10/3/2014David D MuthVPBuy10,000$2.65$26,500.00View SEC Filing  
6/4/2014Steve MillerCOOBuy100,000$2.17$217,000.00View SEC Filing  
5/21/2014Patrick McenanyCEOBuy25,000$1.89$47,250.003,656,247View SEC Filing  
5/19/2014Charles O'keeffeDirectorBuy10,000$1.83$18,300.00192,126View SEC Filing  
4/16/2014Charles O'keeffeDirectorBuy5,000$2.02$10,100.00182,126View SEC Filing  
2/7/2014Patrick McenanyCEOBuy25,000$1.82$45,500.003,631,247View SEC Filing  
2/5/2014Charles O'keeffeDirectorBuy10,000$1.81$18,100.00177,126View SEC Filing  
10/23/2013David S TierneyDirectorBuy8,000$2.03$16,240.00View SEC Filing  
10/21/2013Charles B O'keeffeDirectorBuy10,000$1.84$18,400.00View SEC Filing  
10/21/2013Patrick J McenanyCEOBuy50,000$1.59$79,500.00View SEC Filing  
2/19/2013Patrick J McenanyCEOBuy50,000$0.46$23,000.00View SEC Filing  
12/17/2012Patrick J McenanyCEOBuy100,000$0.45$45,000.00View SEC Filing  
12/8/2012Biomarin Pharmaceutical IncMajor ShareholderBuy5,000,000$0.75$3,750,000.00View SEC Filing  
11/15/2012Patrick J McenanyCEOBuy100,000$0.42$42,000.00View SEC Filing  
11/15/2012Philip H CoelhoDirectorBuy24,000$0.41$9,840.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Catalyst Pharmaceuticals (NASDAQ CPRX) News Headlines

Source:
DateHeadline
 Analysts Anticipate Catalyst Pharmaceuticals (CPRX) Will Post Earnings of -$0.06 Per Share Analysts Anticipate Catalyst Pharmaceuticals (CPRX) Will Post Earnings of -$0.06 Per Share
www.americanbankingnews.com - April 22 at 3:16 PM
Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Trial of Firdapse® in MuSK Antibody ...Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Trial of Firdapse® in MuSK Antibody ...
globenewswire.com - April 21 at 8:19 AM
BRIEF-Catalyst Pharmaceuticals Announces Enrollment Of First Patient In Phase 3 Trial Of Firdapse In Musk Antibody ...BRIEF-Catalyst Pharmaceuticals Announces Enrollment Of First Patient In Phase 3 Trial Of Firdapse In Musk Antibody ...
www.reuters.com - April 21 at 8:19 AM
Catalyst Enrolls First Patient in Phase III Firdapse StudyCatalyst Enrolls First Patient in Phase III Firdapse Study
www.zacks.com - April 20 at 5:21 PM
Your Daily Pharma Scoop: Adamas Update, Shire Bidding War, Novartis ResultsYour Daily Pharma Scoop: Adamas Update, Shire Bidding War, Novartis Results
seekingalpha.com - April 20 at 8:24 AM
Enrollment underway in late-stage study of Catalyst Pharmas Firdapse in subtype of myasthenia gravisEnrollment underway in late-stage study of Catalyst Pharma's Firdapse in subtype of myasthenia gravis
seekingalpha.com - April 19 at 5:40 PM
Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Trial of Firdapse® in MuSK Antibody Positive Myasthenia GravisCatalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Trial of Firdapse® in MuSK Antibody Positive Myasthenia Gravis
finance.yahoo.com - April 19 at 8:16 AM
Catalyst Pharmaceuticals (CPRX) Down 7.4% Since Earnings Report: Can It Rebound?Catalyst Pharmaceuticals (CPRX) Down 7.4% Since Earnings Report: Can It Rebound?
www.zacks.com - April 14 at 8:23 AM
Catalyst Pharmaceuticals (CPRX) Given Consensus Recommendation of "Hold" by AnalystsCatalyst Pharmaceuticals (CPRX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 11 at 3:17 AM
 Analysts Expect Catalyst Pharmaceuticals (CPRX) to Announce -$0.06 Earnings Per Share Analysts Expect Catalyst Pharmaceuticals (CPRX) to Announce -$0.06 Earnings Per Share
www.americanbankingnews.com - April 5 at 3:16 PM
Catalyst Pharmaceuticals Inc (CPRX) Insider Patrick J. Mcenany Acquires 20,000 SharesCatalyst Pharmaceuticals Inc (CPRX) Insider Patrick J. Mcenany Acquires 20,000 Shares
www.americanbankingnews.com - April 3 at 10:44 PM
3 Things In Biotech, April 2: Catalyst Pharm Goes, Pfizer Flows, MediciNova Woes3 Things In Biotech, April 2: Catalyst Pharm Goes, Pfizer Flows, MediciNova Woes
seekingalpha.com - April 3 at 8:23 AM
Catalyst Pharmaceuticals (CPRX) Raised to Hold at Zacks Investment ResearchCatalyst Pharmaceuticals (CPRX) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - April 2 at 7:30 PM
Catyalyst Pharma (CPRX) Announces Submission of NDA for Firdapse for Treatment of LEMSCatyalyst Pharma (CPRX) Announces Submission of NDA for Firdapse for Treatment of LEMS
www.streetinsider.com - March 30 at 8:23 AM
Catalyst Pharmaceuticals files new drug application with FDACatalyst Pharmaceuticals files new drug application with FDA
www.bizjournals.com - March 29 at 5:30 PM
Catalyst Pharma refiles U.S. marketing application for Firdapse for LEMS; shares up 2% premarketCatalyst Pharma refiles U.S. marketing application for Firdapse for LEMS; shares up 2% premarket
seekingalpha.com - March 29 at 5:30 PM
Catalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse® for Treatment of Lambert-Eaton Myasthenic SyndromeCatalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse® for Treatment of Lambert-Eaton Myasthenic Syndrome
finance.yahoo.com - March 29 at 8:27 AM
Catalyst Pharmaceuticals (CPRX) Downgraded by BidaskClub to "Sell"Catalyst Pharmaceuticals (CPRX) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - March 26 at 5:58 PM
UPDATE: Catalyst Pharmaceutical Partners (CPRX) PT Raised to $6 at Roth Capital Following 4Q - StreetInsider.comUPDATE: Catalyst Pharmaceutical Partners (CPRX) PT Raised to $6 at Roth Capital Following 4Q - StreetInsider.com
www.streetinsider.com - March 20 at 8:27 AM
Catalyst Pharmaceuticals Inc (CPRX) Expected to Announce Earnings of -$0.06 Per ShareCatalyst Pharmaceuticals Inc (CPRX) Expected to Announce Earnings of -$0.06 Per Share
www.americanbankingnews.com - March 19 at 3:14 PM
SunTrust Banks Research Analysts Increase Earnings Estimates for Catalyst Pharmaceuticals Inc (CPRX)SunTrust Banks Research Analysts Increase Earnings Estimates for Catalyst Pharmaceuticals Inc (CPRX)
www.americanbankingnews.com - March 19 at 1:54 AM
Catalyst Pharmaceuticals Inc (CPRX) Receives Average Rating of "Hold" from AnalystsCatalyst Pharmaceuticals Inc (CPRX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 17 at 4:00 AM
Catalyst Pharmaceuticals Inc Forecasted to Earn FY2022 Earnings of $0.84 Per Share (CPRX)Catalyst Pharmaceuticals Inc Forecasted to Earn FY2022 Earnings of $0.84 Per Share (CPRX)
www.americanbankingnews.com - March 16 at 4:21 PM
Catalyst Pharmaceuticals (CPRX) Downgraded to "Strong Sell" at BidaskClubCatalyst Pharmaceuticals (CPRX) Downgraded to "Strong Sell" at BidaskClub
www.americanbankingnews.com - March 16 at 2:10 PM
Catalyst (CPRX) Posts In-Line Q4 Loss, Pipeline in Progress - NasdaqCatalyst (CPRX) Posts In-Line Q4 Loss, Pipeline in Progress - Nasdaq
www.nasdaq.com - March 16 at 8:20 AM
Catalyst Pharmaceutical Partners (CPRX) CEO Patrick McEnany on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaCatalyst Pharmaceutical Partners' (CPRX) CEO Patrick McEnany on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 16 at 8:20 AM
Catalyst Pharmaceuticals (CPRX) Stock Rating Reaffirmed by HC WainwrightCatalyst Pharmaceuticals (CPRX) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - March 15 at 3:02 PM
Clinical Hold On IGNITE DMD Douses SLDB, PTI Awaits Data In Q2, CPRX On Watch - NasdaqClinical Hold On IGNITE DMD Douses SLDB, PTI Awaits Data In Q2, CPRX On Watch - Nasdaq
www.nasdaq.com - March 15 at 8:16 AM
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate ... - GlobeNewswire (press release)Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate ... - GlobeNewswire (press release)
globenewswire.com - March 15 at 8:16 AM
Catalyst Pharmaceuticals (CPRX) Issues Quarterly  Earnings Results, Meets ExpectationsCatalyst Pharmaceuticals (CPRX) Issues Quarterly Earnings Results, Meets Expectations
www.americanbankingnews.com - March 15 at 7:56 AM
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate UpdateCatalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 14 at 7:07 PM
When Will Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Breakeven?When Will Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Breakeven?
finance.yahoo.com - March 14 at 7:07 PM
Catalyst Pharmaceuticals Announces Date and Time Change for ... - NasdaqCatalyst Pharmaceuticals Announces Date and Time Change for ... - Nasdaq
www.nasdaq.com - March 13 at 8:25 AM
Catalyst Pharmaceuticals Announces Date and Time Change for Fourth Quarter and Year-End Financial Results Call ... - GlobeNewswire (press release)Catalyst Pharmaceuticals Announces Date and Time Change for Fourth Quarter and Year-End Financial Results Call ... - GlobeNewswire (press release)
globenewswire.com - March 13 at 8:25 AM
Carbon Disulfide Market Worth $165.1 Million By 2025 | CAGR: 2.4% : Grand View Research, Inc.Carbon Disulfide Market Worth $165.1 Million By 2025 | CAGR: 2.4% : Grand View Research, Inc.
www.prnewswire.com - March 12 at 6:40 PM
Catalyst Pharmaceuticals Announces Date and Time Change for Fourth Quarter and Year-End Financial Results Call and WebcastCatalyst Pharmaceuticals Announces Date and Time Change for Fourth Quarter and Year-End Financial Results Call and Webcast
finance.yahoo.com - March 12 at 9:02 AM
Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results Conference Call and Webcast on Thursday, March 15th, 2018Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results Conference Call and Webcast on Thursday, March 15th, 2018
finance.yahoo.com - March 8 at 8:23 AM
Catalyst Pharmaceuticals (CPRX) Scheduled to Post Earnings on TuesdayCatalyst Pharmaceuticals (CPRX) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - March 6 at 2:32 AM
Zacks: Brokerages Expect Catalyst Pharmaceuticals Inc (CPRX) Will Post Earnings of -$0.06 Per ShareZacks: Brokerages Expect Catalyst Pharmaceuticals Inc (CPRX) Will Post Earnings of -$0.06 Per Share
www.americanbankingnews.com - March 2 at 7:42 PM
Catalyst Pharmaceuticals Inc (CPRX) Position Boosted by Broadfin Capital LLCCatalyst Pharmaceuticals Inc (CPRX) Position Boosted by Broadfin Capital LLC
www.americanbankingnews.com - March 2 at 5:08 AM
Catalyst Pharmaceuticals Announces Its Continuing Support for Rare Disease Day 2018 - GlobeNewswire (press release)Catalyst Pharmaceuticals Announces Its Continuing Support for Rare Disease Day 2018 - GlobeNewswire (press release)
globenewswire.com - March 1 at 8:15 AM
Catalyst Pharmaceuticals Announces Its Continuing Support for Rare Disease Day 2018 - NasdaqCatalyst Pharmaceuticals Announces Its Continuing Support for Rare Disease Day 2018 - Nasdaq
www.nasdaq.com - February 28 at 8:17 AM
Catalyst Pharmaceuticals Announces Its Continuing Support for Rare Disease Day 2018Catalyst Pharmaceuticals Announces Its Continuing Support for Rare Disease Day 2018
finance.yahoo.com - February 28 at 8:17 AM
EAM Investors LLC Acquires Shares of 1,042,519 Catalyst Pharmaceuticals Inc (CPRX)EAM Investors LLC Acquires Shares of 1,042,519 Catalyst Pharmaceuticals Inc (CPRX)
www.americanbankingnews.com - February 27 at 3:00 PM
Catalyst Pharmaceuticals Inc (CPRX) Given Average Rating of "Hold" by AnalystsCatalyst Pharmaceuticals Inc (CPRX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - February 20 at 3:28 AM
Catalyst Pharmaceutical (CPRX) Presents At BIO CEO & Investor Conference - SlideshowCatalyst Pharmaceutical (CPRX) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 13 at 3:43 PM
Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for Firdapse®Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for Firdapse®
finance.yahoo.com - February 12 at 9:44 AM
Catalyst Pharmaceuticals to Present at Two Upcoming Investor ConferencesCatalyst Pharmaceuticals to Present at Two Upcoming Investor Conferences
finance.yahoo.com - February 7 at 9:34 AM
Catalyst Pharmaceuticals Inc (CPRX) Receives Average Rating of "Hold" from BrokeragesCatalyst Pharmaceuticals Inc (CPRX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 26 at 3:24 AM
Contrasting TESARO (TSRO) & Catalyst Pharmaceuticals (CPRX)Contrasting TESARO (TSRO) & Catalyst Pharmaceuticals (CPRX)
www.americanbankingnews.com - January 25 at 10:34 AM

SEC Filings

Catalyst Pharmaceuticals (NASDAQ:CPRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Catalyst Pharmaceuticals (NASDAQ:CPRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Catalyst Pharmaceuticals (NASDAQ CPRX) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.